Corrigendum: Host DNA released by NETosis promotes rhinovirus-induced type-2 allergic asthma exacerbation.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

7 citing papers in PubMed.

1. Association ofHeliyon · 2024
   Article
2. Simvastatin Reduces NETosis to Attenuate Severe Asthma by Inhibiting PAD4 Expression.Oxidative medicine and cellular longevity · 2023
   Article
3. Circulating biomarkers of inflammaging as potential predictors of COVID-19 severe outcomes.Mechanisms of ageing and development · 2022
   Review
4. Rhinovirus C Infection Induces Type 2 Innate Lymphoid Cell Expansion and Eosinophilic Airway Inflammation.Frontiers in immunology · 2021
   Article
5. TLR9-IL-2 axis exacerbates allergic asthma by preventing IL-17A hyperproduction.Scientific reports · 2020
   Article
6. Innate immunity in allergy.Allergy · 2019
   Review
7. Rhinovirus Attributes that Contribute to Asthma Development.Immunology and allergy clinics of North America · 2019
   Review

Corrections and comments

• Erratum for
  Host DNA released by NETosis promotes rhinovirus-induced type-2 allergic asthma exacerbation.2017

Authors and funding

16 authors.

Funding

Abstract